3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
3
tislelizumab
1
spartalizumab
1
fludarabine phosphate
1
bemarituzumab
1
Tablets
1
Specimen Handling
1
Solutions
1
Rogaratinib
1
Pemetrexed
1
Magnetic Resonance Spectroscopy
1
Interleukin-13
1
IFL protocol
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Cetuximab
1
Carboplatin
1
Biopsy
1
BID protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
bemarituzumab
×
Head & Neck
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled